- Home
- BNTX vs XPO Comparison
BNTX vs XPO Comparison
Compare BNTX & XPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | XPO |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 21.3B |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BNTX | XPO |
|---|---|---|
| Price | $102.94 | $225.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 18 |
| Target Price | $133.46 | ★ $177.35 |
| AVG Volume (30 Days) | 756.5K | ★ 1.3M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.64 |
| Revenue | N/A | ★ $7,744,000,000.00 |
| Revenue This Year | N/A | $5.79 |
| Revenue Next Year | $4.98 | $6.39 |
| P/E Ratio | ★ N/A | $83.76 |
| Revenue Growth | N/A | ★ 0.34 |
| 52 Week Low | $79.81 | $91.66 |
| 52 Week High | $124.00 | $222.06 |
Technical Indicators
Market Signals| Indicator | BNTX | XPO |
|---|---|---|
| Relative Strength Index (RSI) | 66.07 | 71.74 |
| Support Level | $100.01 | $123.93 |
| Resistance Level | $104.05 | N/A |
| Average True Range (ATR) | 2.67 | 7.45 |
| MACD | 2.01 | 2.36 |
| Stochastic Oscillator | 89.55 | 89.96 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.